Roche Hldg Ltd Spons (RHHBY) 37.4250 $RHHBY
Ilumina files patent infringement suit against Roche subsidiary
Seeking Alpha - at Seeking Alpha - 58 mins ago
ILMN: 200.76 (+1.69)
Lab Automation Market by Equipment & Software, Applications, Type of Automation, & End Users - Global Forecasts to 2020
M2 - Mon May 18, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d4wgt/lab_automation) has announced the addition of the "Lab Automation Market by Equipment & Software, Applications, Type of Automation, & End Users - Global Forecasts to 2020" report to their offering. The global lab automation market is poised to reach $5,105.7 Million by 2020 from $3,474.2 Million in 2014, at a CAGR of 6.7% from 2015 to 2020. Major factors fueling market growth are miniaturization in the process, progressing drug discovery and clinical diagnostics, higher reproducibility and accuracy, and large workforce demand and supply gap. In addition, greater productivity and reduction in costs, better personnel safety, and requirement of small volumes of samples and reagents are further driving market growth. However, lack of planning for technology development and indefinite data interchange are restricting the growth of the lab automation market. The lab automation market is segmented on the basis of equipment and software, application, type of automation, end user, and region. On the basis of type of automation, the lab automation market is segmented into modular automation and total lab automation (TLA). The modular automation segment accounted for the largest share of the market as modular automation is affordable to almost all small-to-medium-sized labs and requires less space. Geographically, the surgical microscopes market is dominated by North America, followed by Europe. Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Lab Automation Market, By Equipment and Software 8 Lab Automation Market, By Application 9 Lab Automation Market, By Type of Automation 10 Lab Automation Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Agilent Technologies - Beckman Coulter, Inc. (Subsidiary of Danaher Corporation) - Biom?rieux SA - Hamilton Robotics, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Holding AG - Siemens Healthcare (Subsidiary of Siemens AG) - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2d...automation
A: 42.63 (+0.59), QGEN: 24.91 (+0.20), DHR: 87.26 (+0.81)
The Weekender
Aviate - at Seeking Alpha - Sun May 17, 7:39AM CDT
Rising rates, banks, beta and the pain trade We note a strategy piece by a well-respected strategist this week (JPMorgan) used the word ' reflation ' - one all but removed from investment parlance - with respect to the bond market's rather vicious...
WMT: 79.92 (+0.68), RBS: 11.05 (-0.08), SPY: 213.10 (+0.66), LYG: 5.53 (-0.10), AV: 16.76 (-0.34), MR: 27.37 (-0.19), PSO: 20.90 (+0.06), LBTYK: 49.67 (+0.24), TI: 12.31 (-0.22), LBTYA: 51.94 (+0.34), BHP: 48.37 (-3.18), TEF: 14.72 (-0.16), DIA: 182.68 (+0.20), ING: 16.37 (-0.22), RIO: 45.64 (-0.49), PHG: 27.91 (-0.42), VOD: 36.51 (-0.53), QQQ: 110.06 (+0.48)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 198.37 (+3.87), VRTX: 127.31 (+1.10), OVAS: 30.01 (+0.84), MYL: 71.38 (+0.71), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), ALR: 50.79 (+0.04), ONTY: 2.59 (+0.16), CELG: 116.37 (+0.84), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), OREX: 4.98 (-0.03), FCSC: 3.92 (-0.10), NVIV: 12.09 (-0.97), GILD: 111.00 (+1.70), GWPH: 112.93 (+0.68), CTSO: 6.24 (+0.31), ACHN: 11.03 (+1.46), RMD: 56.81 (+0.61), SNY: 50.40 (-0.12), PBYI: 181.30 (+4.29)
Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT
PFE: 33.98 (-0.01), AZN: 68.74 (-0.55), LLY: 72.94 (+0.04), SNY: 50.40 (-0.12)
Roche Reports Encouraging Data on Lung Cancer Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 14, 3:30PM CDT
Roche (RHHBY) announced impressive interim data from a phase II study evaluating the use of its immuno-oncology candidate, MPDL3280A.
GILD: 111.00 (+1.70), PFE: 33.98 (-0.01), SNY: 50.40 (-0.12)
Puma Crashes, Roche Rises On Cancer Data News
at Investor's Business Daily - Thu May 14, 11:59AM CDT
Puma Biotechnology (PBYI) stock tumbled Thursday after the company released disappointing data late Wednesday, ahead of the annual American Society for Clinical Oncology meeting. The ASCO abstract release also featured positive but somewhat...
MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36), PBYI: 181.30 (+4.29)
Roche's MPDL3280A doubled overall survival in NSCLC in mid-stage study
Seeking Alpha - at Seeking Alpha - Thu May 14, 9:17AM CDT
Roche's alectinib shows response rates as high as 69% in early stage cancer trials
Seeking Alpha - at Seeking Alpha - Thu May 14, 9:00AM CDT
10 Important Checkpoint Inhibitor Cancer Drug Abstracts from ASCO '15
at The Street - Wed May 13, 4:53PM CDT
The American Society of Clinical Oncology (ASCO) annual meeting will showcase new research into cancer immunotherapies.
PFE: 33.98 (-0.01), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36)
Genentech's Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With Specific Type of Lung Cancer
Business Wire - Wed May 13, 4:00PM CDT
-- Genentech plans to submit these Phase I/II data to the FDA as part of a New Drug Application for alectinib, which has been granted Breakthrough Therapy Designation --
Genentech's Investigational Immunotherapy MPDL3280A Doubled the Likelihood of Survival Compared with Chemotherapy in People with a Specific Type of Lung Cancer
Business Wire - Wed May 13, 4:00PM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from a global, randomized Phase II study (POPLAR) in people with previously treated non-small cell lung cancer (NSCLC). The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 (programmed death ligand-1) compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high (HR=0.56) or any level of PD-L1 expression (HR=0.63), as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 12, 3:00PM CDT
Continued Pipeline Progress in Partnered and Proprietary Programs
QURE: 27.67 (+1.13), XENE: 13.00 (-0.11), ROG: 72.55 (+1.19)
Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT
MDVN: 125.90 (+3.00), JNJ: 103.42 (+1.12)
5 Largest Markets for Pharmaceuticals
Cheryl Swanson, The Motley Fool - Motley Fool - Tue May 12, 9:26AM CDT
Source: Flickr, Creative Commons. If you're a biotech or Big Pharma company, your world is not only growing, it's standing on its head. According to the Institute for Healthcare Informatics, worldwide spending for prescription branded drugs and...
ABT: 48.84 (+0.13), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), JNJ: 103.42 (+1.12), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31)
Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 8:20AM CDT
Inovio Pharmaceuticals, Inc. reported a first-quarter 2015 loss of 18 cents per share, narrower than the year-ago loss of 20 cents.
INO: 8.11 (+0.14), GILD: 111.00 (+1.70), ACOR: 30.71 (+0.67)
Ophthotech moving ahead with Fovista studies
Seeking Alpha - at Seeking Alpha - Mon May 11, 4:22PM CDT
OPHT: 52.05 (+0.03), REGN: 496.74 (+7.73)
FDA clears Roche KRAS test
Seeking Alpha - at Seeking Alpha - Mon May 11, 7:07AM CDT
Regeneron Beats, Raises And Accelerates Its Late-Stage Product Development
DoctoRx - at Seeking Alpha - Mon May 11, 7:02AM CDT
PCYC: 258.23 (+2.81), ISIS: 64.33 (+1.78), AZN: 68.74 (-0.55), ABBV: 65.61 (-0.38), SNY: 50.40 (-0.12), REGN: 496.74 (+7.73), NVS: 104.06 (+0.31)
Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO
Business Wire - Mon May 11, 12:00AM CDT
-- New pivotal results for two medicines, investigational ALK inhibitor alectinib in advanced non-small cell lung cancer (NSCLC) and Gazyva(R) (obinutuzumab) in indolent non-Hodgkin's lymphoma (NHL) --
Ilumina files patent infringement suit against Roche subsidiary
Seeking Alpha - at Seeking Alpha - 58 mins ago
ILMN: 200.76 (+1.69)
Lab Automation Market by Equipment & Software, Applications, Type of Automation, & End Users - Global Forecasts to 2020
M2 - Mon May 18, 4:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2d4wgt/lab_automation) has announced the addition of the "Lab Automation Market by Equipment & Software, Applications, Type of Automation, & End Users - Global Forecasts to 2020" report to their offering. The global lab automation market is poised to reach $5,105.7 Million by 2020 from $3,474.2 Million in 2014, at a CAGR of 6.7% from 2015 to 2020. Major factors fueling market growth are miniaturization in the process, progressing drug discovery and clinical diagnostics, higher reproducibility and accuracy, and large workforce demand and supply gap. In addition, greater productivity and reduction in costs, better personnel safety, and requirement of small volumes of samples and reagents are further driving market growth. However, lack of planning for technology development and indefinite data interchange are restricting the growth of the lab automation market. The lab automation market is segmented on the basis of equipment and software, application, type of automation, end user, and region. On the basis of type of automation, the lab automation market is segmented into modular automation and total lab automation (TLA). The modular automation segment accounted for the largest share of the market as modular automation is affordable to almost all small-to-medium-sized labs and requires less space. Geographically, the surgical microscopes market is dominated by North America, followed by Europe. Asia-Pacific is expected to grow at the highest CAGR during the forecast period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Lab Automation Market, By Equipment and Software 8 Lab Automation Market, By Application 9 Lab Automation Market, By Type of Automation 10 Lab Automation Market, By End User 11 Geographic Analysis 12 Competitive Landscape 13 Company Profiles - Agilent Technologies - Beckman Coulter, Inc. (Subsidiary of Danaher Corporation) - Biom?rieux SA - Hamilton Robotics, Inc. - Perkinelmer, Inc. - Qiagen N.V. - Roche Holding AG - Siemens Healthcare (Subsidiary of Siemens AG) - Tecan Group Ltd. - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/2d...automation
A: 42.63 (+0.59), QGEN: 24.91 (+0.20), DHR: 87.26 (+0.81)
The Weekender
Aviate - at Seeking Alpha - Sun May 17, 7:39AM CDT
Rising rates, banks, beta and the pain trade We note a strategy piece by a well-respected strategist this week (JPMorgan) used the word ' reflation ' - one all but removed from investment parlance - with respect to the bond market's rather vicious...
WMT: 79.92 (+0.68), RBS: 11.05 (-0.08), SPY: 213.10 (+0.66), LYG: 5.53 (-0.10), AV: 16.76 (-0.34), MR: 27.37 (-0.19), PSO: 20.90 (+0.06), LBTYK: 49.67 (+0.24), TI: 12.31 (-0.22), LBTYA: 51.94 (+0.34), BHP: 48.37 (-3.18), TEF: 14.72 (-0.16), DIA: 182.68 (+0.20), ING: 16.37 (-0.22), RIO: 45.64 (-0.49), PHG: 27.91 (-0.42), VOD: 36.51 (-0.53), QQQ: 110.06 (+0.48)
Seeking Alpha's Biotech Weekly: Orexigen's Wreck, Stagnant Gilead, And More
SA Editor Mike Taylor - Seeking Alpha - Fri May 15, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors weighed the options for Orexigen (NASDAQ: OREX ) after the...
PRGO: 198.37 (+3.87), VRTX: 127.31 (+1.10), OVAS: 30.01 (+0.84), MYL: 71.38 (+0.71), AMGN: 163.44 (+1.08), GSK: 44.66 (-0.11), ALR: 50.79 (+0.04), ONTY: 2.59 (+0.16), CELG: 116.37 (+0.84), PVCT: 0.85 (-0.02), JNJ: 103.42 (+1.12), OREX: 4.98 (-0.03), FCSC: 3.92 (-0.10), NVIV: 12.09 (-0.97), GILD: 111.00 (+1.70), GWPH: 112.93 (+0.68), CTSO: 6.24 (+0.31), ACHN: 11.03 (+1.46), RMD: 56.81 (+0.61), SNY: 50.40 (-0.12), PBYI: 181.30 (+4.29)
Dendrimers Coming Of Age: Starpharma's Star Is Rising
Keith Williams - at Seeking Alpha - Fri May 15, 11:05AM CDT
PFE: 33.98 (-0.01), AZN: 68.74 (-0.55), LLY: 72.94 (+0.04), SNY: 50.40 (-0.12)
Roche Reports Encouraging Data on Lung Cancer Drugs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 14, 3:30PM CDT
Roche (RHHBY) announced impressive interim data from a phase II study evaluating the use of its immuno-oncology candidate, MPDL3280A.
GILD: 111.00 (+1.70), PFE: 33.98 (-0.01), SNY: 50.40 (-0.12)
Puma Crashes, Roche Rises On Cancer Data News
at Investor's Business Daily - Thu May 14, 11:59AM CDT
Puma Biotechnology (PBYI) stock tumbled Thursday after the company released disappointing data late Wednesday, ahead of the annual American Society for Clinical Oncology meeting. The ASCO abstract release also featured positive but somewhat...
MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36), PBYI: 181.30 (+4.29)
Roche's MPDL3280A doubled overall survival in NSCLC in mid-stage study
Seeking Alpha - at Seeking Alpha - Thu May 14, 9:17AM CDT
Roche's alectinib shows response rates as high as 69% in early stage cancer trials
Seeking Alpha - at Seeking Alpha - Thu May 14, 9:00AM CDT
10 Important Checkpoint Inhibitor Cancer Drug Abstracts from ASCO '15
at The Street - Wed May 13, 4:53PM CDT
The American Society of Clinical Oncology (ASCO) annual meeting will showcase new research into cancer immunotherapies.
PFE: 33.98 (-0.01), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), BMY: 68.00 (+0.36)
Genentech's Investigational Medicine Alectinib Shrank Tumors in Nearly Half of People With Specific Type of Lung Cancer
Business Wire - Wed May 13, 4:00PM CDT
-- Genentech plans to submit these Phase I/II data to the FDA as part of a New Drug Application for alectinib, which has been granted Breakthrough Therapy Designation --
Genentech's Investigational Immunotherapy MPDL3280A Doubled the Likelihood of Survival Compared with Chemotherapy in People with a Specific Type of Lung Cancer
Business Wire - Wed May 13, 4:00PM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from a global, randomized Phase II study (POPLAR) in people with previously treated non-small cell lung cancer (NSCLC). The study showed the investigational cancer immunotherapy MPDL3280A (anti-PDL1) doubled the likelihood of survival (overall survival [OS]; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 (programmed death ligand-1) compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high (HR=0.56) or any level of PD-L1 expression (HR=0.63), as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).
Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
GlobeNewswire - Tue May 12, 3:00PM CDT
Continued Pipeline Progress in Partnered and Proprietary Programs
QURE: 27.67 (+1.13), XENE: 13.00 (-0.11), ROG: 72.55 (+1.19)
Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT
MDVN: 125.90 (+3.00), JNJ: 103.42 (+1.12)
5 Largest Markets for Pharmaceuticals
Cheryl Swanson, The Motley Fool - Motley Fool - Tue May 12, 9:26AM CDT
Source: Flickr, Creative Commons. If you're a biotech or Big Pharma company, your world is not only growing, it's standing on its head. According to the Institute for Healthcare Informatics, worldwide spending for prescription branded drugs and...
ABT: 48.84 (+0.13), PFE: 33.98 (-0.01), AMGN: 163.44 (+1.08), LLY: 72.94 (+0.04), BMY: 68.00 (+0.36), GSK: 44.66 (-0.11), JNJ: 103.42 (+1.12), GILD: 111.00 (+1.70), MRK: 60.01 (-0.22), ABBV: 65.61 (-0.38), NVS: 104.06 (+0.31)
Inovio Narrows Q1 Loss Y/Y, Misses Earnings Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 12, 8:20AM CDT
Inovio Pharmaceuticals, Inc. reported a first-quarter 2015 loss of 18 cents per share, narrower than the year-ago loss of 20 cents.
INO: 8.11 (+0.14), GILD: 111.00 (+1.70), ACOR: 30.71 (+0.67)
Ophthotech moving ahead with Fovista studies
Seeking Alpha - at Seeking Alpha - Mon May 11, 4:22PM CDT
OPHT: 52.05 (+0.03), REGN: 496.74 (+7.73)
FDA clears Roche KRAS test
Seeking Alpha - at Seeking Alpha - Mon May 11, 7:07AM CDT
Regeneron Beats, Raises And Accelerates Its Late-Stage Product Development
DoctoRx - at Seeking Alpha - Mon May 11, 7:02AM CDT
PCYC: 258.23 (+2.81), ISIS: 64.33 (+1.78), AZN: 68.74 (-0.55), ABBV: 65.61 (-0.38), SNY: 50.40 (-0.12), REGN: 496.74 (+7.73), NVS: 104.06 (+0.31)
Pivotal Data for Genentech Medicines in Lung and Blood Cancers to Be Presented at ASCO
Business Wire - Mon May 11, 12:00AM CDT
-- New pivotal results for two medicines, investigational ALK inhibitor alectinib in advanced non-small cell lung cancer (NSCLC) and Gazyva(R) (obinutuzumab) in indolent non-Hodgkin's lymphoma (NHL) --
